Candriam SCA Portfolio holdings
Candriam is a Luxembourg asset manager with sustainable investing at its core, run as a subsidiary of New York Life Investments, with Belgian bank Belfius holding a minority stake. It was previously Dexia Asset Management and took the Candriam name in 2014, short for "Conviction AND Responsibility In Asset Management", after New York Life's asset management arm acquired it. Its funds span bonds, stocks, absolute return strategies and asset allocation, and its portfolios exclude controversial weapons, thermal coal and tobacco. In 2021 it bought a majority stake in the European real estate manager Tristan Capital Partners.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Abbott
ABT
|
+$98.2M |
| 2 |
Meta Platforms (Facebook)
META
|
+$82.9M |
| 3 |
ServiceNow
NOW
|
+$70.4M |
| 4 |
Intel
INTC
|
+$58.4M |
| 5 |
Salesforce
CRM
|
+$54.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alphabet (Google) Class A
GOOGL
|
+$102M |
| 2 |
Palo Alto Networks
PANW
|
+$102M |
| 3 |
AbbVie
ABBV
|
+$68.9M |
| 4 |
Amazon
AMZN
|
+$57M |
| 5 |
NVIDIA
NVDA
|
+$54.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 41.06% |
| 2 | Healthcare | 24.01% |
| 3 | Financials | 9.02% |
| 4 | Communication Services | 7.08% |
| 5 | Consumer Discretionary | 6.1% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
26
JPMorgan Chase
JPM
$912B
| $170M | 0.76% |
513,198
-31,070
| -6% | -$10.9M |
2014 Q4
47 quarters
|
|
27
Analog Devices
ADI
$198B
| $153M | 0.68% |
384,899
+88,442
| +30% | +$33.3M |
2016 Q1
42 quarters
|
|
28
Amgen
AMGN
$253B
| $149M | 0.66% |
352,483
-10,502
| -3% | -$4.19M |
2016 Q1
42 quarters
|
|
|
29
Intel
INTC
$332B
| $145M | 0.64% |
1,200,085
+572,302
| +91% | +$58.4M |
2014 Q4
47 quarters
|
|
30
NextEra Energy
NEE
$180B
| $143M | 0.64% |
1,880,377
-125,889
| -6% | -$10.6M |
2014 Q4
47 quarters
|
|
31
Johnson & Johnson
JNJ
$675B
| $137M | 0.61% |
516,642
+6,468
| +1% | +$1.71M |
2014 Q4
47 quarters
|
|
32
KLA
KLAC
$210B
| $133M | 0.59% |
681,613
-79,248
| -10% | -$15.5M |
2014 Q4
47 quarters
|
|
33
Regeneron Pharmaceuticals
REGN
$99.2B
| $132M | 0.59% |
173,146
-22,528
| -12% | -$17M |
2014 Q4
47 quarters
|
|
34
Home Depot
HD
$350B
| $122M | 0.54% |
425,924
+46,098
| +12% | +$15.1M |
2014 Q4
47 quarters
|
|
35
UnitedHealth
UNH
$361B
| $119M | 0.53% |
323,073
+13,778
| +4% | +$5.55M |
2014 Q4
47 quarters
|
|
36
CrowdStrike
CRWD
$235B
| $117M | 0.52% |
440,723
-129,457
| -23% | -$27.5M |
2021 Q2
21 quarters
|
|
37
Marvell Technology
MRVL
$152B
| $115M | 0.51% |
434,204
-7,727
| -2% | -$1.73M |
2018 Q1
34 quarters
|
|
38
Tesla
TSLA
$1.54T
| $115M | 0.51% |
322,479
+8,519
| +3% | +$3.05M |
2014 Q4
47 quarters
|
|
|
39
Abbott
ABT
$189B
| $114M | 0.51% |
1,151,288
+940,121
| +445% | +$98.2M |
2016 Q1
42 quarters
|
|
40
Vertex Pharmaceuticals
VRTX
$139B
| $112M | 0.5% |
212,933
+13,428
| +7% | +$6.88M |
2014 Q4
47 quarters
|
|
41
BeOne Medicines Ltd
ONC
$48B
| $106M | 0.47% |
289,235
-500
| -0.2% | -$171K |
2025 Q1
6 quarters
|
|
42
Datadog
DDOG
$66.6B
| $105M | 0.47% |
383,724
+7,980
| +2% | +$1.97M |
2020 Q3
24 quarters
|
|
43
Cadence Design Systems
CDNS
$90.3B
| $103M | 0.46% |
311,375
+32,647
| +12% | +$10.7M |
2018 Q4
31 quarters
|
|
44
Western Digital
WDC
$117B
| $98.5M | 0.44% |
215,886
-407
| -0.2% | -$198K |
2014 Q4
47 quarters
|
|
45
Wabtec
WAB
$51B
| $97.1M | 0.43% |
336,877
-27,157
| -7% | -$7.72M |
2018 Q4
31 quarters
|
|
46
Biogen
BIIB
$37.5B
| $93.5M | 0.42% |
412,472
+28,146
| +7% | +$5.97M |
2014 Q4
47 quarters
|
|
47
Revolution Medicines
RVMD
$39.1B
| $91.8M | 0.41% |
445,693
-110,699
| -20% | -$21.9M |
2021 Q1
22 quarters
|
|
48
Xylem
XYL
$21.8B
| $89M | 0.4% |
875,838
-106,420
| -11% | -$12.2M |
2014 Q4
47 quarters
|
|
49
MongoDB
MDB
$27.2B
| $88.3M | 0.39% |
252,296
-28,285
| -10% | -$10.7M |
2020 Q2
25 quarters
|
|
50
GE Vernova
GEV
$214B
| $87.7M | 0.39% |
91,920
-21,765
| -19% | -$21.6M |
2024 Q2
9 quarters
|
|
Similar funds
Candriam SCA's Q3 2026 Portfolio in Review
As of Q3 2026, Candriam SCA held 699 positions worth $22.5B, up 1.4% from $22.2B the previous quarter. Its ten largest holdings account for 34% of the portfolio.
Candriam SCA's Q3 2026 filing shows 21 new, 252 increased, 270 reduced and 51 closed positions. Its largest new stake was Zenas BioPharma: 654,833 shares worth $17.7M. The largest sale was Alphabet (Google) Class A, an estimated $102M.
By sector, the portfolio is most concentrated in Technology at 41% of assets, up from 38% a quarter earlier, followed by Healthcare and Financials.
- Candriam SCA's largest Q3 2026 buy was Zenas BioPharma: 654,833 shares worth $17.7M.
- Candriam SCA added most to Abbott in Q3 2026, an estimated $98.2M increase.
- Candriam SCA's biggest Q3 2026 reduction was Alphabet (Google) Class A, cutting an estimated $102M.
- Candriam SCA fully exited StoneX in Q3 2026, selling an estimated $46.1M.
- Candriam SCA's ten largest holdings make up 34% of its $22.5B portfolio in Q3 2026.
- Candriam SCA opened 21 new positions and closed 51 in Q3 2026.
- Candriam SCA's portfolio value rose 1.4% quarter-over-quarter to $22.5B.
Based on Candriam SCA's 13F filing for Q3 2026, filed 3 Nov 2026.